ERBB2 and ductal breast carcinoma in situ: With respect to high preop-NLR, there was no significant difference between the TNBC and ER-positive and HER2-positive group (64.9% vs. 63.6% vs. 71.4%, p = 0.60) in our DCIS cohort.